Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016| Dave Fornell

Update for LAA Occluder Technology News and Trends

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA). The standard of care is use of warfarin or newer anticoagulation therapy agents, but there has been growing interest in eliminating the need for these drugs and their associated increased bleeding risks by closing off the LAA to prevent clot formation. Device therapy now exists for both open surgical and transcatheter LAA occlusion. 

Below are links to recent DAIC articles that offer an update on this cardiovascular technology area:

 

Occluding the Left Atrial Appendage (LAA)

VIDEO - Post-FDA Approval Experience of LAA Occluders at ACC.16

FDA Approves Pivotal Trial for St, Jude's Amulet LAA Occluder

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Societies Issue Recommendations for Left Atrial Appendage Occlusion

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

Medicare Will Cover Watchman Left Atrial Appendage Closure Device

AtriCure Receives FDA Clearance for New AtriClip Device

New Study Demonstrates Cost-Effectiveness of Watchman Device

Boston Scientific Receives CE Mark For Next-generation Watchman FLX LAA Closure Device

FDA Announces Safety Issues With Lariat Left Atrial Appendage (LAA) Closure Device

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

AtriCure Receives CE Mark for AtriClip PRO2 Device

New Data Supports St. Jude Medical FFR and LAA Closure Technology

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Valley Hospital Begins Enrollment for aMAZE Trial

AtriCure Enrolls First Patient in ATLAS Study

Role of Interventional Echocardiography in Transcatheter Structural Heart Procedures

 

Related Content

News | Antiplatelet and Anticoagulation Therapies| January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies| November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies| November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init